Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Treatment Effects of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) in Participants With Alzheimer's Disease (AD)

NCT05332678 is registered in ClinicalTrials.gov with Seelos Therapeutics, Inc. as lead sponsor.

NCT NCT05332678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05332678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Treatment Effects of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) in Participants With Alzheimer's Disease (AD)
Lead sponsor
Seelos Therapeutics, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
March 3, 2023
Completion date
April 10, 2023
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease